Please assess the completion status of the following clinical trial:

Trial Title: Reduced PCV Dosing Schedules in South African Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent by the parent/guardian of the child;~2. Born to an HIV-uninfected women, based on testing undertaken as part of standard of care during the last trimester of pregnancy;~3. Had not received any vaccine other than BCG and OPV (routinely given at birth) prior to enrolment;~4. Birth weight \>2499g AND weight of child \>3.5 kg at time of proposed randomization;~5. Aged 42-56 days of age at time of enrolment;~6. Available for the duration of the study;~7. Child is healthy based on medical history and physical examination of the study-staff.~Exclusion Criteria:~1. Any clinically significant major congenital abnormalities;~2. Previous hospitalization for a respiratory illness following discharge from hospital after birth;~3. Receipt of any other investigational drug/vaccine. Co-enrollment into non-investigational studies, including epidemiology studies, is allowed;~4. Any previous PCV vaccination;~5. Known allergy to any of the vaccine components;~6. Febrile illness (axillary temperature ≥37.8°C) at time of enrolment. These participants are eligible if the temperature resolves for at least 48 hours and they remain within the study defined window periods;~7. Planned relocation to outside of the study area during up until age of 2 years;~8. Receipt of blood transfusion or any other blood products (including immunoglobulins) since birth. Receipt of such products during the course of the study, will require withdrawal of the child from the study;~9. History of confirmed pneumococcal disease since birth;~10. Any known or suspected immunodeficiency condition which could affect immune response to vaccination.

- Gender: ALL
- Minimum Age: 5 Weeks
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- Group 1a (1+1, 6 weeks) (Type: EXPERIMENTAL): PCV10 (Synflorix 0.5ml injection) will be administered at 6 weeks and 9 months of age
- Group 1b (1+1, 6 weeks) (Type: EXPERIMENTAL): PCV13 (Prevenar 13, 0.5ml injection) will be administered at 6 weeks and 9 months of age
- Group 2a (1+1, 14 weeks) (Type: EXPERIMENTAL): PCV10 (Synflorix 0.5ml injection) will be administered at 14 weeks and 9 months of age
- Group 2b (1+1, 14 weeks) (Type: EXPERIMENTAL): PCV13 (Prevenar 13, 0.5ml injection) will be administered at 14 weeks and 9 months of age
- Group 3a (2+1) (Type: ACTIVE_COMPARATOR): PCV10 (Synflorix 0.5ml injection) will be administered at 6 weeks, 14 weeks and 9 months of age, as per EPI schedule in South Africa
- Group 3b (2+1) (Type: ACTIVE_COMPARATOR): PCV13 (Prevenar 13, 0.5ml injection) will be administered at 6 weeks, 14 weeks and 9 months of age, as per EPI schedule in South Africa

Based on this trial design, predict the completion outcome and termination type (if applicable).